| Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer (NCT04191460) | Erasmus Medical Center | 2022-07-12 |
| Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region (NCT05482880) | Maastricht University Medical Center | 2022-02-28 |
| A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (NCT04830592) | Akamis Bio | 2021-11-04 |
| Needs and Preferences of Patients With Head-neck Cutaneous SCC (NCT06046625) | Maastricht University Medical Center | 2021-11-01 |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (NCT05059444) | Guardant Health, Inc. | 2021-09-07 |
| Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. (NCT04881045) | Pfizer | 2021-08-18 |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 (NCT04787042) | Simcha IL-18, Inc. | 2021-08-06 |
| Study of HLA-DR in Cell Cultures Isolated From Primary Squamous Cell Carcinoma (NCT06041464) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2021-03-02 |
| Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (NCT04609566) | Seagen, a wholly owned subsidiary of Pfizer | 2021-01-26 |
| Patient Reported Outcomes Study Using Electronic Monitoring System for Advanced or Metastatic Solid Cancer (NCT05931445) | Comprehensive Support Project for Oncology Research | 2021-01-26 |
| Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck (NCT03513042) | Leiden University Medical Center | 2021-01-21 |
| Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data. (NCT04672772) | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | 2020-12-18 |
| Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors (NCT04628780) | Pfizer | 2020-12-16 |
| Hemopurifier Plus Pembrolizumab in Head and Neck Cancer (NCT04453046) | Aethlon Medical Inc. | 2020-10-22 |
| Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (NCT04590963) | AstraZeneca | 2020-10-02 |
| Study of Pharmacokinetic, Safety, Immunogenicity and Efficacy of CMAB819 and Nivolumab in R/M HNSCC (NCT04659369) | Taizhou Mabtech Pharmaceutical Co.,Ltd | 2020-09-24 |
| A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) (NCT04459715) | EMD Serono Research & Development Institute, Inc. | 2020-08-07 |
| CIML NK Cell in Head & Neck Cancer (NCT04290546) | Dana-Farber Cancer Institute | 2020-07-20 |
| Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (NCT04326257) | Dan Zandberg | 2020-05-14 |
| Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (NCT03946358) | Centre Hospitalier Universitaire de Besancon | 2020-02-18 |
| De-Escalation Therapy for Human Papillomavirus Negative Disease (NCT03944915) | University of Chicago | 2019-08-26 |
| IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma (NCT03381183) | H. Lee Moffitt Cancer Center and Research Institute | 2019-08-21 |
| Hyperbaric Radiation Sensitization of Head and Neck Cancers (NCT03843671) | National Baromedical Services | 2019-07-01 |
| Study of TQB2450 in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck（R/M SCCHN） (NCT03855384) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2019-06-11 |
| A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (NCT03849469) | Xencor, Inc. | 2019-05-29 |
| FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (NCT03723967) | Centre Leon Berard | 2019-05-16 |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors (NCT03645928) | Iovance Biotherapeutics, Inc. | 2019-05-07 |
| A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (NCT03752398) | Xencor, Inc. | 2019-05-01 |
| SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas (NCT03894618) | Shattuck Labs, Inc. | 2019-03-26 |
| Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN (NCT03880396) | Assiut University | 2019-03-10 |
| Paclitaxel (Albumin Bound),Bleomycin And Cisplatin Or Carboplatin for Recurrent Or Metastatic Squamous Cell Carcinoma Of The Head And Neck (NCT03830385) | Sun Yat-sen University | 2019-02-15 |
| IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors (NCT03758781) | H. Lee Moffitt Cancer Center and Research Institute | 2019-02-13 |
| Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer (NCT03733210) | Andrei Iagaru | 2019-01-07 |
| A Study of Treatment Patterns and Clinical Outcomes in First Line Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (1L R/M SCCHN) Participants in Europe (NCT05123950) | Bristol-Myers Squibb | 2019-01-01 |
| Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors (NCT03689192) | Herlev Hospital | 2018-12-17 |
| Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck (NCT03139058) | Centre Hospitalier Universitaire, Amiens | 2018-12-13 |
| Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy (NCT03712566) | University Health Network, Toronto | 2018-11-06 |
| VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer (NCT03690986) | Emory University | 2018-11-01 |
| Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC (NCT03646461) | University of California, San Diego | 2018-10-17 |
| A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077) | Incyte Corporation | 2018-09-24 |
| Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine (NCT03633110) | Genocea Biosciences, Inc. | 2018-08-29 |
| Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC (NCT03624231) | Ulrich Keilholz | 2018-08-15 |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies (NCT03629756) | Arcus Biosciences, Inc. | 2018-07-24 |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (NCT03517488) | Xencor, Inc. | 2018-07-10 |
| Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC (NCT03552965) | University of Arkansas | 2018-06-19 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. (NCT03525392) | Ipsen | 2018-05-03 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| Impact of Ribociclib on Head and Neck Squamous Cell Cancer (NCT03179956) | Fox Chase Cancer Center | 2018-04-02 |
| Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN (NCT03341936) | Dana-Farber Cancer Institute | 2018-03-15 |
| Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (NCT03325465) | University of Chicago | 2018-01-22 |
| Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer (NCT03349710) | Bristol-Myers Squibb | 2017-12-15 |
| Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD (NCT03246685) | HiberCell, Inc. | 2017-11-08 |
| Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma (NCT03938012) | National University Hospital, Singapore | 2017-10-03 |
| Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. (NCT03245736) | Seagen Inc. | 2017-08-23 |
| PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck (NCT02819752) | Royal Marsden NHS Foundation Trust | 2017-07-12 |
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160) | Threshold Pharmaceuticals | 2017-05-10 |
| A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study (NCT02841748) | University of Chicago | 2017-05-10 |
| The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck (NCT03057613) | Case Comprehensive Cancer Center | 2017-05-10 |
| Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN) (NCT03129061) | CellSight Technologies, Inc. | 2017-05-01 |
| A Study Evaluating MM-310 in Patients With Solid Tumors (NCT03076372) | Merrimack Pharmaceuticals | 2017-02-22 |
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck (NCT03083873) | Iovance Biotherapeutics, Inc. | 2017-01-09 |
| The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy (NCT03202173) | Eye & ENT Hospital of Fudan University | 2017-01-01 |
| Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100) (NCT02952586) | Pfizer | 2016-11-28 |
| Ipilimumab for Head and Neck Cancer Patients (NCT02812524) | Providence Health & Services | 2016-11-18 |
| Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck. (NCT02882308) | Hellenic Cooperative Oncology Group | 2016-10-20 |
| Expansion Trial for Axitinib In Head And Neck Cancer (NCT02762513) | University of Michigan Rogel Cancer Center | 2016-08-30 |
| A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck (NCT02054442) | Radboud University Medical Center | 2016-08-01 |
| Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck (NCT02769520) | Assuntina G. Sacco, MD | 2016-07-06 |
| CTC Detection Rate in SCCHN With a in Vivo Device (NCT03071900) | Nanjing Tongren Hospital | 2016-06-22 |
| Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC (NCT02707588) | Groupe Oncologie Radiotherapie Tete et Cou | 2016-05-18 |
| GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients (NCT02575404) | Providence Health & Services | 2016-05-16 |
| Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) (NCT02573493) | Washington University School of Medicine | 2016-04-13 |
| Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors (NCT02636036) | Akamis Bio | 2016-01-25 |
| Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck (NCT01998542) | Mirror Biologics, Inc. | 2016-01-01 |
| Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion (NCT03330249) | Groupe Oncologie Radiotherapie Tete et Cou | 2015-12-03 |
| Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer (NCT02551159) | AstraZeneca | 2015-10-15 |
| ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors (NCT02565758) | AbbVie | 2015-09-18 |
| SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) (NCT02543476) | AstraZeneca | 2015-09-16 |
| Safety Study of MGD009 in B7-H3-expressing Tumors (NCT02628535) | MacroGenics | 2015-09-01 |
| Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer (NCT02572778) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-09-01 |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (NCT02277197) | James J Lee | 2015-08-01 |
| Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib (NCT02538627) | Merrimack Pharmaceuticals | 2015-08-01 |
| A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors (NCT02452424) | Daiichi Sankyo | 2015-07-02 |
| Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma (NCT02454179) | Acerta Pharma BV | 2015-05-01 |
| Safety Study of AMG 228 to Treat Solid Tumors (NCT02437916) | Amgen | 2015-04-21 |
| Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies (NCT02369458) | Washington University School of Medicine | 2015-04-14 |
| Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck (NCT02429089) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2015-04-01 |
| Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma (NCT02296684) | Washington University School of Medicine | 2015-03-25 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (NCT02624128) | National Cancer Institute, Naples | 2015-02-23 |
| Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer (NCT02350712) | Daiichi Sankyo | 2014-12-01 |
| Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy (NCT02972216) | Yung Shin Pharm. Ind. Co., Ltd. | 2014-11-01 |
| A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab (NCT02124850) | Celgene | 2014-10-28 |
| A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer (NCT02262741) | MedImmune LLC | 2014-10-15 |
| Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck (NCT02158234) | H. Lee Moffitt Cancer Center and Research Institute | 2014-07-16 |
| Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN (NCT02124707) | UNC Lineberger Comprehensive Cancer Center | 2014-06-16 |
| Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) (NCT02105636) | Bristol-Myers Squibb | 2014-05-29 |
| Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial (NCT02765503) | International Atomic Energy Agency | 2014-03-01 |
| Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer (NCT02031250) | University of Michigan Rogel Cancer Center | 2014-02-01 |
| ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer (NCT02002182) | Andrew Sikora | 2013-12-01 |